Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Is it time for PET-guided therapy in follicular lymphoma?

Judith Trotman, Andrew R. Pettitt

Blood (2022) 139 (11): 1631–1641.

https://doi.org/10.1182/blood.2020008243

Published: 2022

Journal Articles

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

Blood (2016) 128 (22): 1218.

https://doi.org/10.1182/blood.V128.22.1218.1218

Published: 2016

Journal Articles

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Andy C Rawstron, BSc, PhD, Talha Munir, Samuel Muñoz-Vicente, Kristian Brock, MSc, BSc, Francesca J Yates, PhD MSci, Rebecca Bishop, BSc, Surita Dalal, Ruth Mary de Tute, PhD FRCPath, Adrian Bloor, Oonagh M Sheehy, MB BSc FRCP FRCPAth, Andrew R. Pettitt, Christopher P Fox, MBChB, MRCP, FRCPath, Christopher Fegan, Stephen Devereux, PhD FRCP, FRCPath, Donald Macdonald, Peter Hillmen

Blood (2016) 128 (22): 2049.

https://doi.org/10.1182/blood.V128.22.2049.2049

Published: 2016

Journal Articles

Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot

Pauline Robbe, Kate Ridout, Jennifer Becq, Miao He, Ruth Clifford, MD, Reem Alsolami, Adam Burns, Samantha JL Knight, Melanie Oates, Dena Howard, Andrew R. Pettitt, Augusto Rendon, Niko Popitsch, Peter Hillmen, Jenny C Taylor, Mark Caulfield, David Bentley, Clare Turnbull, Anna Schuh, MD PhD

Blood (2016) 128 (22): 2022.

https://doi.org/10.1182/blood.V128.22.2022.2022

Published: 2016

Journal Articles

Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia

Karl-Anton Kreuzer, Richard R. Furman, Stephan Stilgenbauer, Ronald L. Dubowy, Yeonhee Kim, Veerendra Munugalavadla, Esther Lilienweiss, Hans Christian Reinhardt, Andrew R. Pettitt, Michael Hallek

Blood (2016) 128 (22): 192.

https://doi.org/10.1182/blood.V128.22.192.192

Published: 2016

Journal Articles

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia

Blood (2015) 126 (23): 365.

https://doi.org/10.1182/blood.V126.23.365.365

Published: 2015

Journal Articles

Genomic Dissection of the Fcγ Receptor Region in the Context of Monoclonal Antibody Therapy

Chantal Hargreaves, PhD, Chisako Iriyama, MD PhD, Matthew JJ Rose-Zerilli, PhD, Charlotte Lee, BSc, Kathleen Potter, PhD, Rosalind Ganderton, Khiyam Hussain, Lee Machado, PhD, Edward Hollox, Sarah E Coupland, MBBS, PhD, Michael Stackpole, Melanie Oates, PhD, Andrew R. Pettitt, PhD MRCPath, Mark Cragg, PhD, Jonathan C Strefford, PhD

Blood (2014) 124 (21): 2996.

https://doi.org/10.1182/blood.V124.21.2996.2996

Published: 2014

Journal Articles

The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays

Samantha JL Knight, PhD CBiol, MSB, FRCPath, Ruth Clifford, MD, Pauline Robbe, MSc, Sara DC Ramos, MSc, Adam Burns, BSc, Adele T Timbs, MSc, Reem Alsolami, BSc, Susanne Weller, PhD, Angela Hamblin, MDPhD, Joanne Mason, PhD, Melanie Oates, PhD, Michalis Titsias, PhD, Christopher Yau, DPhil, Chris C Holmes, PhD, Andrew R Pettitt, FRCP, PhD, Peter Hillmen, MB, ChB, PhD, Jenny Taylor, DPhil, Anna Shuh, MD PhD FRCP, FRCPath

Blood (2014) 124 (21): 3315.

https://doi.org/10.1182/blood.V124.21.3315.3315

Published: 2014

Journal Articles

Total Proteome Analysis Identifies Migration Defects As a Major Pathogenetic Factor in IGHV-Unmutated Chronic Lymphocytic Leukemia

Gina L Eagle, PhD, Rosalind E Jenkins, PhD, Kathleen J Till, PhD, Jithesh Puthen, PhD, Ke Lin, PhD, Gillian G Johnson, PhD, Melanie Oates, PhD, Kevin Park, PhD, Neil R Kitteringham, PhD, Jianguo Zhuang, PhD, Andrew R Pettitt, MRCP, PhD

Blood (2014) 124 (21): 718.

https://doi.org/10.1182/blood.V124.21.718.718

Published: 2014

Journal Articles

Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing

Blood (2014) 124 (21): 1974.

https://doi.org/10.1182/blood.V124.21.1974.1974

Published: 2014

Journal Articles

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Andy Rawstron, PhD, Claudia Fazi, PhD, Neus Villamor, MD PhD, Julio Delgado, MD PhD, Remi Letestu, MD PhD, Florence Cymbalista, MD, Carlos Palacio, Francesc Bosch, MD PhD, Ruth M De Tute, MSc, Stuart Liptrot, David O'Brien, FAMLs, Martin Spacek, MD, PhD, Johan Dobber, Arnon P. Kater, MD PhD, Peter C Gambell, David A Westerman, MBBS, FRACP, FRCPA, Asha Soosapilla, Stephen P. Mulligan, MBBS, PhD FRACP, FRCPA, Gerard Lozanski, MD, Ke Lin, PhD, Andrew R Pettitt, MRCP, PhD, Gabi Brachtl, Alexander Egle, MD, David W Williamson, PhD, Catherine M Sanders, PhD, Harlan Robins, PhD, Justin Boysen, Tait D. Shanafelt, MD, Curtis A. Hanson, MD, Jeffrey L. Jorgensen, MD PhD, William G. Wierda, MD PhD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Laura Rassenti, PhD, H. Elizabeth Broome, MD, Thomas J. Kipps, MD PhD, Mathieu Hauwel, Iuri Marinov, Fiona E. Craig, MBBS, Nomdedeu Josep, Carol Moreno, MD, Olga Stehlikova, MSc., Michael Doubek, Sarka Pospisilova, Prof., Dr., PhD, Karl-Anton Kreuzer, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Emili Montserrat, MD PhD, Paolo Ghia, MD

Blood (2014) 124 (21): 1976.

https://doi.org/10.1182/blood.V124.21.1976.1976

Published: 2014

Journal Articles

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

Gillian G. Johnson, Ke Lin, Trevor F. Cox, Melanie Oates, David R. Sibson, Richard Eccles, Bryony Lloyd, Laura-Jayne Gardiner, Daniel F. Carr, Munir Pirmohamed, Jonathan C. Strefford, David G. Oscier, David Gonzalez de Castro, Monica Else, Daniel Catovsky, Andrew R. Pettitt

Blood (2013) 122 (26): 4253–4258.

https://doi.org/10.1182/blood-2013-07-516666

Published: 2013

Includes: Supplemental data

Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2013) 122 (21): LBA-6.

https://doi.org/10.1182/blood.V122.21.LBA-6.LBA-6

Published: 2013

Journal Articles

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, Richard A Jones, Andy Rawstron, PhD, J Sheila, Paul Evans, Carter Anthony, Claire E. Dearden, MD, Estella Matutes, Andrew R. Pettitt, PhD, MRCPath, Daniel B. Kennedy, Sharon Barrans, Lisa Worrillow, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 922.

https://doi.org/10.1182/blood.V116.21.922.922

Published: 2010

Journal Articles

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A. Follows, Donald Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David G. Oscier, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Andy Rawstron, PhD, Christopher F.E. Pocock, MD, PhD

Blood (2010) 116 (21): 697.

https://doi.org/10.1182/blood.V116.21.697.697

Published: 2010

Journal Articles

Identification of Novel Recurrent Copy Number Variations and Regions of Copy-Neutral Loss of Heterozygosity by High Resolution Genomic Array in Pre-Treatment and Relapsed B-CLL.

Samantha JL Knight, Elham Sadighi Akha, Adele Timbs, Tariq Enver, Andrew R Pettitt, Jenny Taylor, Chris S Hatton, Anna Schuh

Blood (2009) 114 (22): 1098.

https://doi.org/10.1182/blood.V114.22.1098.1098

Published: 2009

Journal Articles

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A Follows, Donald W. Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David Oscier, MD, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Walter M Gregory, Andy C. Rawstron, PhD, Colin R.W. Hayward, MBBS, Christopher Pocock

Blood (2009) 114 (22): 3428.

https://doi.org/10.1182/blood.V114.22.3428.3428

Published: 2009

Journal Articles

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

Peter Hillmen, MBChB, PhD, Christopher Pocock, MB, BS, PhD, Dena Cohen, MSc, Kim Cocks, MSc, Hazem A. Sayala, MB, BCh, Andy Rawstron, PhD, Daniel B. Kennedy, MB, ChB, Christopher Fegan, MB, BS, Don W. Milligan, MB, ChB, Claire Dearden, MB, BS, Alexandra Smith, BSc, Emma Lindop, BSc, Andrew R. Pettitt, MB, BChir, PhD

Blood (2007) 110 (11): 752.

https://doi.org/10.1182/blood.V110.11.752.752

Published: 2007

Journal Articles

Targeting DNA-PK and ATM Increases Sensitivity to Chlorambucil and Fludarabine in Chemoresistant and p53-Defective B-CLL Cells.

Elaine Willmore, PhD, Geoffrey P. Summerfield, MD, Tryfonia Mainou-Fowler, PhD, Graham H. Jackson, MD, Anthony Carter, Andrew R. Pettitt, MD, Barbara W. Durkacz, PhD

Blood (2006) 108 (11): 523.

https://doi.org/10.1182/blood.V108.11.523.523

Published: 2006

Journal Articles

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

Hazem A. Sayala, MD, Paul Moreton, MD, Richard A. Jones, PhD, Andy C. Rawstron, PhD, Sheila J. O’Connor, PhD, Paul Evans, PhD, Carter Anthony, MsC, Claire Dearden, MD, Estella Matutes, MD, PhD, Andrew R. Pettitt, MD, PhD, Daniel B. Kennedy, MD, Peter Hillmen, MD, PhD

Blood (2006) 108 (11): 34.

https://doi.org/10.1182/blood.V108.11.34.34

Published: 2006

NARROW

Is it time for PET-guided therapy in follicular lymphoma?

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot

Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia

Genomic Dissection of the Fcγ Receptor Region in the Context of Monoclonal Antibody Therapy

The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays

Total Proteome Analysis Identifies Migration Defects As a Major Pathogenetic Factor in IGHV-Unmutated Chronic Lymphocytic Leukemia

Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Identification of Novel Recurrent Copy Number Variations and Regions of Copy-Neutral Loss of Heterozygosity by High Resolution Genomic Array in Pre-Treatment and Relapsed B-CLL.

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

Targeting DNA-PK and ATM Increases Sensitivity to Chlorambucil and Fludarabine in Chemoresistant and p53-Defective B-CLL Cells.

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only